These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 14650830)

  • 1. Prognostic factors for metastatic kidney cancer.
    Drucker BJ; Mazumdar M; Motzer RJ
    Cancer Treat Res; 2003; 116():139-53. PubMed ID: 14650830
    [No Abstract]   [Full Text] [Related]  

  • 2. Inflammatory response predicts survival in renal cancer.
    Kerr C
    Lancet Oncol; 2006 Apr; 7(4):284. PubMed ID: 16598873
    [No Abstract]   [Full Text] [Related]  

  • 3. External validation of the systemic immune-inflammation index as a prognostic factor in metastatic renal cell carcinoma and its implementation within the international metastatic renal cell carcinoma database consortium model.
    Chrom P; Zolnierek J; Bodnar L; Stec R; Szczylik C
    Int J Clin Oncol; 2019 May; 24(5):526-532. PubMed ID: 30604160
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic, clinicopathological, and immune correlation of NLRP3 promoter methylation in kidney renal clear cell carcinoma.
    Long Q; He L; Peng J; Meng Q; Zhang C; Chen M; Wang X; Zhu W; Zheng F; Dong P; Deng W
    Clin Transl Med; 2021 Oct; 11(10):e528. PubMed ID: 34709757
    [No Abstract]   [Full Text] [Related]  

  • 5. The relation between lymphocyte-monocyte ratio and renal cell carcinoma.
    Balta S; Demirer Z; Aparci M; Demirkol S; Ozturk C
    Urol Oncol; 2015 Oct; 33(10):421. PubMed ID: 26048105
    [No Abstract]   [Full Text] [Related]  

  • 6. [Expression of LeX antigens in renal adenocarcinoma differentiation and the prognosis].
    Fukushi Y; Saito S; Orikasa S; Ohtani H
    Nihon Hinyokika Gakkai Zasshi; 1988 Jun; 79(6):1090-5. PubMed ID: 2903265
    [No Abstract]   [Full Text] [Related]  

  • 7. New therapeutic developments in renal cell cancer.
    Prenen H; Gil T; Awada A
    Crit Rev Oncol Hematol; 2009 Jan; 69(1):56-63. PubMed ID: 18752971
    [TBL] [Abstract][Full Text] [Related]  

  • 8. HLA class I expression in primary and metastatic renal cell carcinoma.
    Buszello H; Ackermann R
    Investig Urol (Berl); 1994; 5():55-9. PubMed ID: 7719321
    [No Abstract]   [Full Text] [Related]  

  • 9. Dendritic cells for the treatment of metastatic renal cell carcinoma: at a low ebb?
    Patard JJ
    Eur Urol; 2006 Jul; 50(1):11-3. PubMed ID: 16713068
    [No Abstract]   [Full Text] [Related]  

  • 10. Inhibition of lymphocyte proliferative responses by renal cell carcinoma extract.
    Malinowski K; Kono K; Takayama T; Terashima T; Tsukuda K; Waltzer W; Rapaport FT
    Transplant Proc; 1997; 29(1-2):839-41. PubMed ID: 9123549
    [No Abstract]   [Full Text] [Related]  

  • 11. Circulating cancer cells in renal-cell carcinoma.
    Pontes JE; Pescatori E; Connelly R; Hashimura T; Tubbs R
    Prog Clin Biol Res; 1990; 348():1-12. PubMed ID: 2385602
    [No Abstract]   [Full Text] [Related]  

  • 12. [Immunohistochemical characterization of renal cell carcinomas].
    Bohle B; Waldherr R; Schwechheimer K; Moldenhauer G; Momburg F
    Verh Dtsch Ges Pathol; 1986; 70():274-8. PubMed ID: 3825252
    [No Abstract]   [Full Text] [Related]  

  • 13. Prognostic factors in renal cell and bladder cancer.
    Van Brussel JP; Mickisch GH
    BJU Int; 1999 May; 83(8):902-8; quiz 908-9. PubMed ID: 10368227
    [No Abstract]   [Full Text] [Related]  

  • 14. New horizons in the treatment of renal cell cancer.
    Wagstaff J
    Ann Oncol; 2006 Sep; 17 Suppl 10():x19-22. PubMed ID: 17018722
    [No Abstract]   [Full Text] [Related]  

  • 15. Presence of tumour-infiltrating FOXP3+ lymphocytes correlates with immature tumour angiogenesis in renal cell carcinomas.
    Zhan HL; Gao X; Zhou XF; Pu XY; Wang DJ
    Asian Pac J Cancer Prev; 2012; 13(3):867-72. PubMed ID: 22631663
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Immunohistochemical study of renal cell carcinoma with monoclonal anti Leu-M1 antibody].
    Senga Y; Satomi Y; Fukuda M; Ebato T; Hosaka M; Tanaka Y; Misugi K
    Nihon Hinyokika Gakkai Zasshi; 1987 Jul; 78(7):1246-51. PubMed ID: 3500350
    [No Abstract]   [Full Text] [Related]  

  • 17. [Renal cell carcinoma and prognostic factors].
    Edeline J; Rioux-Leclercq N
    Ann Pathol; 2008 Oct; 28(5):374-80. PubMed ID: 19068392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular markers in renal cell carcinoma: not quite ready for "prime time".
    Thrasher JB
    Cancer; 1999 Dec; 86(11):2195-7. PubMed ID: 10590356
    [No Abstract]   [Full Text] [Related]  

  • 19. Combination immunotherapy in renal cell carcinoma.
    Drake CG
    Clin Adv Hematol Oncol; 2016 Feb; 14(2):99-100. PubMed ID: 27057808
    [No Abstract]   [Full Text] [Related]  

  • 20. The operable renal cell carcinoma: summary and conclusions.
    deKernion JB; Huland H
    Eur Urol; 1990; 18 Suppl 2():48-51. PubMed ID: 2226611
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.